BR112022003282A2 - Glicovariantes de igm - Google Patents

Glicovariantes de igm

Info

Publication number
BR112022003282A2
BR112022003282A2 BR112022003282A BR112022003282A BR112022003282A2 BR 112022003282 A2 BR112022003282 A2 BR 112022003282A2 BR 112022003282 A BR112022003282 A BR 112022003282A BR 112022003282 A BR112022003282 A BR 112022003282A BR 112022003282 A2 BR112022003282 A2 BR 112022003282A2
Authority
BR
Brazil
Prior art keywords
igm
heavy chain
variant
derived
glycovariants
Prior art date
Application number
BR112022003282A
Other languages
English (en)
Portuguese (pt)
Inventor
Bruce Keyt
Dean Ng
Ramesh Baliga
Original Assignee
Igm Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igm Biosciences Inc filed Critical Igm Biosciences Inc
Publication of BR112022003282A2 publication Critical patent/BR112022003282A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112022003282A 2019-08-23 2020-08-21 Glicovariantes de igm BR112022003282A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962891263P 2019-08-23 2019-08-23
PCT/US2020/047495 WO2021041250A1 (en) 2019-08-23 2020-08-21 Igm glycovariants

Publications (1)

Publication Number Publication Date
BR112022003282A2 true BR112022003282A2 (pt) 2022-05-24

Family

ID=74684266

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022003282A BR112022003282A2 (pt) 2019-08-23 2020-08-21 Glicovariantes de igm

Country Status (11)

Country Link
US (1) US20220306760A1 (https=)
EP (1) EP4017533A4 (https=)
JP (1) JP2022545682A (https=)
KR (1) KR20220050166A (https=)
CN (1) CN114269380A (https=)
AU (1) AU2020337333A1 (https=)
BR (1) BR112022003282A2 (https=)
CA (1) CA3149350A1 (https=)
IL (1) IL290253A (https=)
MX (1) MX2022002239A (https=)
WO (1) WO2021041250A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3560954T3 (pl) 2014-04-03 2021-12-13 Igm Biosciences, Inc. Zmodyfikowany łańcuch J
IL308212A (en) 2015-01-20 2024-01-01 Igm Biosciences Inc Tumor necrosis factor-α receptor binding molecules and their uses
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
EP3355913B1 (en) 2015-09-30 2024-10-30 IGM Biosciences, Inc. Binding molecules with modified j-chain
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
MX2021014973A (es) 2019-06-07 2022-04-18 Adimab Llc Anticuerpos anti-cd3 de alta afinidad y metodos para su generacion y uso.
EP4377360A4 (en) * 2021-09-17 2025-10-15 Adimab Llc Anti-cd3 antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME00832B (me) * 2007-03-22 2012-03-20 Ucb Biopharma Sprl Vezivni proteini uključujući antitjela, derivate antitjela i fragmente antitjela, koji specifično vezuju cd154 i njihova upotreba
CA2780221A1 (en) * 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
PL3560954T3 (pl) * 2014-04-03 2021-12-13 Igm Biosciences, Inc. Zmodyfikowany łańcuch J
EP3355913B1 (en) * 2015-09-30 2024-10-30 IGM Biosciences, Inc. Binding molecules with modified j-chain
WO2017106462A1 (en) * 2015-12-18 2017-06-22 Biogen Ma Inc. Bispecific antibody platform
WO2018136825A1 (en) * 2017-01-19 2018-07-26 Cedars-Sinai Medical Center Highly multiplexed and mass spectrometry based methods to measuring 72 human proteins
MA49279A (fr) * 2017-03-22 2020-02-05 Hoffmann La Roche Compositions d'anticorps optimisées pour le traitement de troubles oculaires
CA3083363A1 (en) * 2017-12-01 2019-06-06 Novartis Ag Polyomavirus neutralizing antibodies

Also Published As

Publication number Publication date
IL290253A (en) 2022-04-01
WO2021041250A1 (en) 2021-03-04
EP4017533A1 (en) 2022-06-29
JP2022545682A (ja) 2022-10-28
CA3149350A1 (en) 2021-03-04
EP4017533A4 (en) 2024-03-27
US20220306760A1 (en) 2022-09-29
MX2022002239A (es) 2022-03-22
CN114269380A (zh) 2022-04-01
KR20220050166A (ko) 2022-04-22
AU2020337333A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
BR112022003282A2 (pt) Glicovariantes de igm
BR112017026704A2 (pt) uso
BR112022011669A2 (pt) Anticorpos biespecíficos caninizados e parceiros de ligação biespecíficos para tratar dermatite atópica
BR112017025332A2 (pt) anticorpos específicos de receptor de célula t
BR112021008060A2 (pt) Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento
CL2024002319A1 (es) Anticuerpo de cadena pesada que se unen a cd22; composición farmacéutica; y su uso.
BR112021016947A2 (pt) Anticorpos que reconhecem tau
BRPI0809665B8 (pt) anticorpo monoclonal que se liga especificamente a endosialina
BR112017005517A2 (pt) anticorpos antiage para o tratamento de inflama-ção e de transtornos autoimunes
BR112018076525A2 (pt) membros de ligação a lag-3
BR112018013677A2 (pt) proteínas de fusão de ligação de 41bb multivalentes e multiespecíficas
MX2023013246A (es) Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usandolo.
BR112018003326A2 (pt) anticorpos de ligação de linfopoietina estromal tímica (tslp) e métodos de uso dos anticorpos
BR112019022906A2 (pt) Anticorpos que reconhecem tau
CL2023003695A1 (es) Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, métodos de uso
BR112017019617A2 (pt) Anticorpo, composto conjugado anticorpo- fármaco anti-cd48, composição de conjugado anticorpo-fármaco, métodos para tratar um paciente com um câncer que expressa cd48, para produzir um anticorpo anti-cd48 e para produzir um conjugado anticorpo-fármaco anti-cd48, ácido nucléico isolado, vetor isolado, e, célula hospedeira isolada
BR112022024262A2 (pt) Métodos de tratamento de nefropatia por iga com um anticorpo de ligação a april
BR112021013397A2 (pt) Anticorpos anti-tigit
BR112021026890A2 (pt) Composições de anticorpo para interromper biofilmes
BR112019004990A2 (pt) anticorpo que se liga especificamente a il-17a e fragmento funcional do mesmo
BR112018073945A2 (pt) métodos para tratamento de miastenia grave generalizada refratária
BR112018003494A2 (pt) anticorpo anti-epha4
BR112021023540A2 (pt) Agentes de afinidade
MX2017009680A (es) Anticuerpos de dominio simple dirigidos al grupo de diferenciación 1d (cd1d).
BR112022008730A2 (pt) Epítopo de antígeno de superfície de células t reguladoras e um anticorpo que se liga especificamente ao mesmo